New Blood Filter May Treat Deadly Pregnancy Condition

For the first time, doctors may have found a way to actually treat preeclampsia instead of just managing it until emergency delivery.

Preeclampsia causes dangerously high blood pressure during pregnancy and affects up to 8% of expectant mothers. Until now, the only solution has been early delivery, which often means premature babies facing serious health challenges.

Researchers at Cedars-Sinai Medical Center tested a blood-filtering treatment on 16 pregnant patients with severe preeclampsia. The technique, called apheresis, works like kidney dialysis by removing a specific protein from the bloodstream while the mother's blood circulates through a machine.

The target is a protein called sFlt-1, which normally helps regulate blood vessel growth around the placenta. In preeclampsia, this protein surges to dangerous levels too early, damaging blood vessels throughout the body.

The treatment proved completely safe for both mothers and babies. Each session reduced the harmful protein levels, and the pregnant patients carried their babies for a median of 10 days longer than untreated patients, who typically delivered within just four days of hospital admission.

Those extra days matter enormously. Every additional week a baby stays in the womb before 32 weeks dramatically reduces risks of breathing problems, developmental disabilities, and other complications from premature birth.

Dr. Ravi Thadhani, the study's co-author, hopes the therapy can "prevent this disease from getting worse and forcing the hand of the obstetrician to deliver" too early. His team first tested the approach on pregnant baboons, then healthy volunteers, before carefully moving to pregnant patients.

Why This Inspires

This breakthrough represents decades of research finally paying off for families facing impossible choices. Preeclampsia doesn't just threaten pregnancies. It can permanently damage a mother's liver, kidneys, and heart, and can escalate to eclampsia, causing seizures, coma, or death.

The small study focused specifically on early-onset preeclampsia diagnosed before 34 weeks, when sFlt-1 levels tend to be highest. While larger clinical trials are needed to confirm how well the treatment works, the safety results clear the path for testing it on more patients.

Researchers acknowledge that preeclampsia isn't one-size-fits-all, and multiple factors beyond this single protein may drive the disease in different women. But for mothers with the early, severe form linked to high sFlt-1 levels, this therapy offers something that's never existed before: hope for a targeted treatment instead of racing against the clock.

After years without options, families finally have reason to believe preeclampsia won't always mean choosing between two difficult outcomes.